| |
Improvement or no change in diastolic function(n=67) |
Worsening of diastolic function
(n=14) |
P value |
| Demographics |
|
|
|
| Age, yrs |
47.8±15.3 |
57.1±6.7 |
0.028 |
| Female gender |
53 (79.1%) |
14 (100%) |
0.060 |
| Nationality |
|
|
0.49 |
| Lebanese |
54(80.6%) |
12(85.7%) |
|
| Iraqi |
11(16.4%) |
1(7.1%) |
|
| Others |
2 (3.0%) |
1(7.1%) |
|
| Body mass index, kg/m2 (n=80) |
26.7±4.8 |
30.9±7.2 |
0.008 |
| Body surface area, m2 (n=80) |
1.77±0.17 |
1.85±0.21 |
0.11 |
| Comorbidities |
|
|
|
| Systolic blood pressure, mm Hg (n=73) |
125±16 |
134±20 |
0.094 |
| Hypertension |
16(23.9%) |
4(28.6%) |
0.71 |
| Diabetes |
9(13.4%) |
1(7.1%) |
0.5 |
| Prior revascularization |
7(10.4%) |
2(14.3%) |
0.68 |
| Smoking history |
26(38.8%) |
6(42.9%) |
0.78 |
| Sedentary lifestyle |
56(83.6%) |
14(100%) |
0.10 |
| Cancer type |
|
|
|
| Breast cancer |
49(73.1%) |
13(92.9%) |
0.11 |
| Lymphoma |
7(10.4%) |
0(0%) |
0.34 |
| Other |
11(16.4%) |
1(7.1%) |
0.68 |
| Creatinine, mg/dL (n=77) |
0.69±0.18 |
0.70±0.22 |
0.87 |
| Glomerular filtration rate, ml/min/1.72m2 (n=76) |
135±49 |
136±39 |
0.91 |
| Medications |
|
|
|
| Beta blockers |
16(23.9%) |
4(28.6%) |
0.71 |
| ACEi/ARB |
16(23.9%) |
1(7.1%) |
0.16 |
| Statins |
11(16.4%) |
3 (21.4%) |
0.65 |
| Anthracyclines or monoclonalantibodies based tyrosine kinaseinhibitors |
25(37.3%) |
10(71.4%) |
0.019 |
|
